
PLRX Stock Forecast & Price Target
PLRX Analyst Ratings
Bulls say
Pliant Therapeutics Inc has positioned itself with a robust scientific foundation, underpinned by the promising clinical data from its lead product candidate, PLN-101095, which has shown significant efficacy and tolerability in monotherapy treatment. The company's proprietary integrin-targeted delivery platform presents additional potential for unlocking value across various disease areas, further bolstered by an accelerated development plan that includes initiation of a Phase 1b trial. Additionally, the experienced management team minimizes risk associated with execution and regulatory interactions, instilling confidence in Pliant's competitive standing in a growing market for integrin-based therapies.
Bears say
Pliant Therapeutics Inc faces significant risks associated with the clinical development of its lead product candidate, PLN-101095, particularly given the historical challenges related to integrin inhibitors. The potential for clinical setbacks can lead to delays or outright failures in drug development, raising concerns about the viability of its pipeline. Additionally, the company's recent decrease in market capitalization can be attributed to an updated cash position and increased share counts, further highlighting financial instability and investor uncertainty.
This aggregate rating is based on analysts' research of Pliant Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
PLRX Analyst Forecast & Price Prediction
Start investing in PLRX
Order type
Buy in
Order amount
Est. shares
0 shares